Supplemental Table 1. Real-world time on treatment among patients with R/M HNSCC who initiated second-line systemic therapy on or before June 30, 2019

|  |  |  |
| --- | --- | --- |
|  |  | Second-line therapy |
|  |  | All patients(N=571) | I-O monotherapy(N=387) | Non-I-O therapy(N=172) |
| Discontinued, N (%) |  | 497 (87.0%) | 320 (82.7%) | 167 (97.1%) |
| Patient follow-up, months A |  | 7.0 (6.2 - 7.7) | 6.4 (5.4 - 7.4) | 8.2 (7.2 - 10.1) |
| Time on treatment, months B |  | 2.3 (2.0 - 2.6) | 2.8 (2.1 - 3.0) | 1.9 (1.4 - 2.2) |
| On-treatment rate C |  |  |  |  |
| 6 months |  | 20.1% (16.9 - 23.6) | 26.7% (22.3 - 31.3) | 5.61% (2.77 - 9.89) |
| 12 months |  | 12.5% (9.80 - 15.6) | 17.9% (14.0 - 22.2) | 1.25% (0.25 - 4.06) |
| 18 months |  | 7.97% (5.56 - 10.9) | 11.6% (8.11 - 15.8) | - |

I-O, immuno-oncology

A Patient follow-up was defined as time from second-line initiation to date of death or data cutoff, whichever occurred first. Values are presented as median (95% CI) months.

B Time on second-line therapy. Values are presented as median (95% CI). Based on the Kaplan-Meier time-to-event model.

C Values are presented as percent (95% CI). Based on the Kaplan-Meier time-to-event model.